Related Experiment Videos
Use of clodronate in multiple myeloma
E Jantunen1, R Lahtinen, M Laakso
1Department of Medicine, Kuopio University Hospital, Finland.
Leukemia & Lymphoma
|October 1, 1995
Summary
Clodronate, a bisphosphonate, effectively treats hypercalcemia and reduces bone lesions in multiple myeloma patients. It is recommended for all active multiple myeloma cases, improving quality of life.
Area of Science:
- Oncology
- Pharmacology
Background:
- Multiple myeloma frequently causes debilitating bone disease, including osteoporosis, osteolytic lesions, fractures, and hypercalcemia.
- These bone complications significantly impair patient quality of life through pain and immobilization.
Purpose of the Study:
- To evaluate the efficacy of clodronate in managing bone disease associated with multiple myeloma.
- To assess the role of clodronate as an adjunctive therapy in active multiple myeloma.
Main Methods:
- Review of existing studies on clodronate treatment in multiple myeloma patients.
- Analysis of clodronate's impact on hypercalcemia, osteolytic lesions, vertebral fractures, and pain.
Main Results:
- Clodronate demonstrates effectiveness in treating hypercalcemia.
- It reduces the progression of osteolytic lesions and the incidence of vertebral fractures.
- Clodronate may also provide pain relief for multiple myeloma patients.
Conclusions:
- Oral clodronate is a safe and effective adjunctive treatment for multiple myeloma.
- It should be considered for all patients with active disease, regardless of initial bone lesion presence.
- Clodronate plays a significant role in the comprehensive management of multiple myeloma.